The global blood testing market size was valued at USD 100.7 billion in 2025 and is projected to grow from USD 107.80 billion in 2026 to USD 185.91 billion by 2034, registering a CAGR of 7.05% during the forecast period from 2026 to 2034. North America dominated the blood testing market with a market share of 38.5% in 2025.
The procedure of examining a person's blood to identify and track various medical disorders is called "blood testing" in the global market. In today's medicine, blood tests are crucial for disease diagnosis, treatment efficacy monitoring, and risk factor screening. Blood testing examines various components in the blood or counts different types of blood cells. Blood tests are prescribed to check disease pathogens or agents, check for antibodies or tumor markers, or see how well-desired treatments work. Blood tests help physicians evaluate the working conditions of organs, diagnose diseases and risk factors for heart disease, check if medicines are working, check for cases of infection or genetic conditions, and determine how well the blood is clotting.
Download a Free Sample To learn more about this report,
Liquid Biopsy Moving Deeper into Cancer Monitoring
Circulating tumor DNA is giving clinicians a less invasive way to track molecular signs of cancer after treatment. This transition is moving liquid biopsy beyond initial tumor profiling toward minimal residual disease assessment and therapy monitoring; in May 2026, the FDA approved Natera’s Signatera CDx for ctDNA-based molecular residual disease detection in muscle-invasive bladder cancer. The result is a broader role for blood testing in precision oncology, post-treatment surveillance, and treatment planning.
Multi-Cancer Detection Expanding the Scope of Blood-Based Screening
Cell-free DNA analysis is allowing one blood sample to be assessed for molecular signals linked with several cancer types. This transition is bringing methylation-based testing into broader screening research; in September 2026, the FDA scheduled an advisory committee review of GRAIL’s Galleri test, which is designed to identify cancer-specific methylation patterns and predict the likely tissue of origin. The result is a wider screening role for blood testing, with potential to support earlier investigation across multiple cancers from a single test.
Higher Burden of Chronic and Metabolic Diseases and Expansion of Point-of-Care Blood Testing Drive Market
The high burden of diabetes, cardiovascular disease, kidney disorders, and other chronic conditions increases demand for routine blood testing used in diagnosis and ongoing disease monitoring. WHO’s 2025 NCD update identifies cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes as the major causes of premature NCD deaths, reinforcing the need for regular detection and screening. Blood glucose, HbA1c, lipid, renal-function, and related tests therefore generate recurring testing volumes across hospitals and diagnostic laboratories.
Wider availability of point-of-care testing increases the supply of blood-testing services outside centralized laboratories, particularly across clinics, emergency departments, and primary-care settings. Compact systems allow healthcare providers to obtain results closer to the patient and reduce dependence on laboratory sample transport for selected tests. The FDA’s current CLIA-waived test database includes blood-related analytes such as glucose, cholesterol, creatinine, platelet count, and prothrombin time, illustrating the expanding range of tests that can be performed in simpler testing environments. This supply-side transition broadens testing access and increases the number of settings capable of performing routine blood analysis.
Shortage of Skilled Laboratory Professionals and Reimbursement and Affordability Constraints Restrain Market Expansion
Limited availability of trained technicians, pathologists, and laboratory specialists reduces the capacity of facilities to process and interpret blood tests efficiently. Staff shortages can increase turnaround times, workload, and operating costs, particularly in smaller and underserved healthcare settings. This workforce gap restricts testing capacity and slows broader market expansion.
Limited or inconsistent reimbursement for specialized blood tests can increase out-of-pocket costs for patients and budget pressure for healthcare providers. This affordability barrier restricts testing volumes and slows wider adoption.
Development of Companion Diagnostic Blood Tests for Targeted Therapies and Expansion of Blood Testing in Transplant Compatibility and Post-Transplant Monitoring
Diagnostic companies, pharmaceutical partners, molecular testing laboratories, and precision-medicine providers represent the main players for this opportunity. Companion blood tests can create revenue through therapy-linked assays, co-development agreements, laboratory services, and recurring testing across treatment pathways. Companies such as Roche, QIAGEN, and Guardant Health are well positioned through their precision diagnostics and oncology testing capabilities.
Transplant diagnostics companies, hospital laboratories, immunology specialists, and reference laboratories form the key commercial groups for this opportunity. Specialized blood tests can create revenue through HLA typing, immune-status assessment, rejection-risk monitoring, and repeat post-transplant testing services. Companies such as Thermo Fisher Scientific, Bio-Rad, and CareDx are positioned to benefit through established transplant diagnostics and monitoring portfolios.
Maintaining Test Accuracy Across Complex and High-Throughput Workflows and Data Interoperability and Fragmented Laboratory Information Systems
Blood testing providers must maintain consistent analytical performance across large sample volumes, different specimen conditions, instruments, and testing environments. Errors in calibration, sample handling, or assay performance can trigger repeat testing, recalls, and weaker clinician confidence, making scale-up harder. In 2025, Cepheid recalled its Xpert BCR-ABL Ultra assay because specimens with very high white blood cell counts could produce inaccurate results.
Modern blood testing increasingly depends on seamless data exchange among analyzers, laboratory information systems, electronic health records, and point-of-care platforms. Fragmented data structures and weak interoperability can delay result reporting, complicate automation, and raise implementation workloads for laboratories and diagnostic companies. These integration gaps make it harder for market players to scale connected testing networks efficiently across multiple healthcare settings.
The solutions segment dominated the blood testing market with a market share of 78.6% in 2025, supported by extensive use of analyzers, reagents, test kits, consumables, and integrated diagnostic platforms across routine and specialized testing workflows. Its broad role in sample processing and result generation keeps it central to laboratory operations.
The software segment is expected to grow at the fastest CAGR of 9.12% during the forecast period 2026–2034, driven by wider adoption of laboratory information systems, automated result interpretation, workflow management, and connectivity between diagnostic instruments and clinical records.
Request Customizationto receive a tailored report.
The glucose testing segment dominated the blood testing market with a market share of 27.8% in 2025 and is also expected to register the fastest CAGR of 8.46% during the forecast period 2026–2034. Its leading position is supported by frequent monitoring requirements for diabetes management, routine health screening, and point-of-care testing across hospitals, clinics, and home settings.
The lipid panel testing segment remains important for cardiovascular risk assessment, while prostate specific antigen (PSA) testing supports prostate health evaluation. Blood urea nitrogen (BUN) testing is widely used for kidney function assessment, thyroid stimulating hormone testing supports thyroid disorder diagnosis, and the others segment includes additional hematology and chemistry-based blood tests.
The automated segment dominated the blood testing market with a market share of 71.9% in 2025 and is also expected to register the fastest CAGR of 8.35% during the forecast period 2026–2034. High sample throughput, standardized processing, reduced manual handling, and faster turnaround times make automated systems well suited to large diagnostic laboratories and hospital testing departments.
The manual segment continues to serve low-volume laboratories, specialized procedures, and settings where testing workflows require greater operator involvement or simpler equipment.
The hospitals & clinics segment dominated the blood testing market with a market share of 44.7% in 2025, supported by continuous testing needs across emergency care, inpatient monitoring, chronic disease management, surgery, and routine diagnosis. Access to integrated laboratory infrastructure and immediate clinical decision-making further supports its strong position.
The remote testing segment is expected to grow at the fastest CAGR of 10.24% during the forecast period 2026–2034, driven by wider use of home-based collection, portable diagnostic devices, and decentralized testing models. Diagnostic centers remain important for high-volume outpatient testing, while the others segment includes research laboratories and additional specialized testing settings.
Speak to an Analystto discuss market opportunities.
The North America blood testing market accounted for the largest regional share of 38.5% in 2025, supported by widespread preventive screening, advanced laboratory networks, chronic disease monitoring, and adoption of automated diagnostic platforms. The U.S. blood testing market benefits from broad use of laboratory testing across diabetes, cardiovascular disease, oncology, infectious diseases, and routine health assessments, sustaining recurring testing volumes across hospitals and outpatient laboratories.
The Canada blood testing market is supported by public health programs focused on earlier detection and long-term monitoring of chronic conditions, alongside continued expansion of laboratory and primary-care diagnostic services. Greater integration of blood testing with preventive care and disease-management pathways supports routine use of chemistry, hematology, immunoassay, and molecular testing.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe blood testing market is expected to register the fastest CAGR of 8.74% during the forecast period, supported by decentralized diagnostics, preventive screening programs, laboratory automation, and aging populations. The U.K. blood testing market benefits from expansion of Community Diagnostic Centres, with £237 million announced in 2026 for new and expanded facilities after the NHS delivered a record 29 million diagnostic tests in 2025; these centres provide services including blood tests closer to patients’ homes.
The Germany blood testing market is supported by demographic aging, with one-quarter of the population projected to be aged 67 or older by 2035, increasing the need for laboratory monitoring of age-associated chronic conditions. The France blood testing market is supported by preventive healthcare and organized disease-detection programs, which strengthen the role of laboratory biomarkers in early diagnosis and ongoing treatment monitoring.
The Asia Pacific blood testing market is expected to grow at a CAGR of 8.31% during the forecast period, supported by broader diagnostic access, chronic disease programs, laboratory modernization, and expansion of preventive healthcare. The Japan blood testing market benefits from an aging population and established health-check systems, sustaining routine laboratory monitoring for metabolic, cardiovascular, and other age-related conditions.
The China blood testing market is supported by the Healthy China 2030 framework, which targets full life-cycle chronic disease management by 2030 and promotes earlier screening for cancer, cardiovascular disease, diabetes, and other conditions. China’s 2024–2030 diabetes program also encourages people aged 40 and above to receive fasting blood-glucose testing at least annually, directly supporting recurring blood-testing volumes. The South Korea market benefits from established national health-screening infrastructure, while the India blood testing market is supported by expansion of primary healthcare and diagnostic access across public and private healthcare networks.
The Blood Testing Market is moderately consolidated, with multinational diagnostics companies, laboratory technology providers, point-of-care testing firms, and specialized assay developers competing across routine diagnostics, disease screening, and advanced molecular testing. Leading players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, and Thermo Fisher Scientific, which together are estimated to account for approximately 40–45% of the global market share.
Established players compete through broad test portfolios, strong laboratory relationships, regulatory capabilities, and integrated diagnostic platforms. Emerging and regional players within the Blood Testing Market ecosystem compete through niche assay development, competitive pricing, faster product customization, and localized distribution, helping them build positions in specialized and underserved testing segments.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com